Detalhe da pesquisa
1.
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.
Ann Oncol
; 31(5): 626-633, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32205017
2.
Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.
J Neurooncol
; 139(1): 107-116, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29637509
3.
Phase I trial outcomes in older patients with advanced solid tumours.
Br J Cancer
; 114(3): 262-8, 2016 Feb 02.
Artigo
Inglês
| MEDLINE | ID: mdl-26757260
4.
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
Ann Oncol
; 27(6): 1013-1019, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-26961146
5.
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Br J Cancer
; 113(11): 1541-7, 2015 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26554652
6.
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents.
Br J Cancer
; 107(11): 1797-800, 2012 Nov 20.
Artigo
Inglês
| MEDLINE | ID: mdl-23099802
7.
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.
Ann Oncol
; 23(5): 1241-1249, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21903605
8.
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
Ann Oncol
; 23(8): 1968-1973, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22408187
9.
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
Ann Oncol
; 23(5): 1307-1313, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22015452
10.
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.
Oncology
; 83(4): 177-82, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-22889980
11.
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
Br J Cancer
; 103(1): 12-7, 2010 Jun 29.
Artigo
Inglês
| MEDLINE | ID: mdl-20588278
12.
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Br J Cancer
; 103(3): 332-9, 2010 Jul 27.
Artigo
Inglês
| MEDLINE | ID: mdl-20628389
13.
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
Ann Oncol
; 21(1): 109-13, 2010 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-19608618
14.
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Ann Oncol
; 24(5): 1416-8, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23524863
15.
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Target Oncol
; 11(3): 401-15, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27169564
16.
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Br J Cancer
; 98(5): 894-9, 2008 Mar 11.
Artigo
Inglês
| MEDLINE | ID: mdl-18319713